WEBINAR: Lecture series Cancer Research: "Role of stromal heterogeneity in metastatic spread and immunotherapy resistance in cancer" - Dr Fatima Mechta-Grigoriou
22/04/2021 11:00 to 22/04/2021 12:15 (Europe/Luxembourg)
Cancer Associated Fibroblasts (CAF) constitute one of the most abundant stromal components in solid tumors. By combining various approaches and CAF markers, we identiﬁed 4 CAF subsets (CAF-S1 to CAF-S4) in breast and ovarian cancers (Costa, Cancer Cell, 2018; Givel, Nat. Commun, 2018). Two myoﬁbroblastic CAF subsets CAF-S1 (FAP+ SMA+ MCAM-) and CAF-S4 (FAP- SMA+MCAM+) accumulate strictly in cancer, while the two others are also detected in normal healthy tissues. CAF-S1 and CAF-S4 display pro-metastatic functions through complementary mechanisms (Pelon, Nat. Commun, 2020; Bonneau, Breast Cancer Res., 2020). In addition, CAF-S1 promote immunosuppression through a multi-step mechanism. Indeed, CAF-S1 attract CD4+CD25+ T lymphocytes, enhance their survival and stimulate their differentiation into CD25HighFOXP3High regulatory T cell (Tregs) (Costa, Cancer Cell, 2018; Givel, Nat. Commun, 2018). By using single cell technology on more than 19,000 single CAF-S1 ﬁbroblasts from breast cancer and demonstrated that the CAF-S1 subset is heterogenous and composed of 8 cellular clusters. We validated the ﬁve most abundant clusters by ﬂow cytometry and in silico analyses in other cancer types, highlighting their relevance. Myoﬁbroblasts from clusters 0 and 3, characterized by extracellular matrix proteins and TGFβ signaling, respectively, are indicative of primary resistance to immunotherapies. Cluster 0/ECM-myCAF upregulates PD-1 and CTLA-4 protein levels in Tregs, which, in turn, increases CAF-S1 cluster 3/TGFβ-myCAF cellular content. Thus, our study highlights a positive feedback loop between speciﬁc CAF-S1 clusters and Tregs and uncovers their role in immunotherapy resistance (Kieffer, Cancer Discovery, 2020).
About the Lecture & Workshop series - CANCER RESEARCH
The LIH lecture and workshops series in Cancer Research, supported by the FNR and jointly organized with the University of Luxembourg, are gathering internationally recognised speakers to address topics around Cancer Research during 2020. Please find here the current programme for 2021.
These lectures will be followed by a workshop especially dedicated to early-stage researchers.
Attendance to the lecture and workshop are free of charge.